Last update 01 Jun 2024

Vericiguat

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
维利西呱, BAY 102, BAY 1021189
+ [7]
Target
Mechanism
sGC stimulants(Soluble guanylate cyclase stimulants)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (19 Jan 2021),
RegulationFast Track (US), Priority Review (CN), Conditional marketing approval (CN), Special Review Project (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC19H16F2N8O2
InChIKeyQZFHIXARHDBPBY-UHFFFAOYSA-N
CAS Registry1350653-20-1

External Link

KEGGWikiATCDrug Bank
D11051-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Reduced ejection fraction co-occurrent and due to chronic heart failure
CN
18 May 2022
Chronic heart failure
EU
16 Jul 2021
Chronic heart failure
IS
16 Jul 2021
Chronic heart failure
LI
16 Jul 2021
Chronic heart failure
NO
16 Jul 2021
Heart Failure
US
19 Jan 2021
Shock
US
19 Jan 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Left ventricular systolic dysfunctionPhase 3-03 Jun 2024
Heart failure with reduced ejection fractionPhase 3-20 Sep 2016
Heart failure with normal ejection fractionPhase 2
US
06 Nov 2013
Heart failure with normal ejection fractionPhase 2
JP
06 Nov 2013
Heart failure with normal ejection fractionPhase 2
AU
06 Nov 2013
Heart failure with normal ejection fractionPhase 2
AT
06 Nov 2013
Heart failure with normal ejection fractionPhase 2
BE
06 Nov 2013
Heart failure with normal ejection fractionPhase 2
BG
06 Nov 2013
Heart failure with normal ejection fractionPhase 2
CA
06 Nov 2013
Heart failure with normal ejection fractionPhase 2
CZ
06 Nov 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
Heart failure with normal ejection fraction
N-terminal pro-B-type natriuretic peptide levels
-
wqucgthtun(dlvcqgbazy) = eazilfvshp kkewfseluh (ukttmzjhwr )
-
22 Jan 2024
Placebo
wqucgthtun(dlvcqgbazy) = abylsdswtp kkewfseluh (ukttmzjhwr )
Not Applicable
Diabetes Mellitus | Heart Failure
type 2 diabetes mellitus
5,048
rugcdqhdro(bmlsnrihqb): HR = 0.91 (95% CI, 0.8 - 1.03)
Positive
28 Aug 2023
Placebo
Not Applicable
-
-
vericiguat
maaruupglb(bcrirusfji) = kzpughsvib nkrjdlxaaq (nzuxspxnlu )
-
28 Aug 2023
Phase 3
5,050
(LVEF ≤24%)
sytylagsos(eoklzvtyck) = bpyoguqsny jogeefpbww (ajqfvebpww )
-
01 May 2023
(LVEF 25%-33%)
sytylagsos(eoklzvtyck) = tkskycjafs jogeefpbww (ajqfvebpww )
Phase 3
5,050
rprqeiwnpn(copqattrhj): OR = 1.45 (95% CI, 1.28 - 1.65); HR = 0.96 (95% CI, 0.95 - 0.99)
Positive
01 Sep 2022
Placebo
Not Applicable
4,805
muiaggrith(brpzwflumw) = Serious adverse events were more frequent in NT-proBNP Q4 (total population) compared with Q1-Q3 (38.3 vs. 32.3%) ekozpyytrf (tuvqbebrpf )
-
26 Jul 2022
Placebo
Not Applicable
5,048
pzqgqtutbs(octfdwznuw) = daposkkgld cjguhyxrca (ahwjqcdclm )
-
01 May 2022
Placebo
pzqgqtutbs(octfdwznuw) = zbdgirfbfk cjguhyxrca (ahwjqcdclm )
Phase 3
1,719
-
Negative
02 Nov 2021
Placebo
Phase 2
456
Placebo
ddsqwyhxjn(gxqkoowtss) = unimyhjcav ddigpcybcr (ftdrzympzb, zolghauipp - idysensoly)
-
25 Mar 2021
Phase 2
477
Placebo
jrlbadfevj(vbkogymjgv) = odxdjsybmv zoiqxruokv (uyunmpbcrt, lxtxujtlej - edjxunsvsn)
-
12 Feb 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free